

116TH CONGRESS 1ST SESSION H.R. 2038

To allow State-based, market-oriented, prescription drug negotiations to lower pharmaceutical drug prices, to encourage competition, to increase consumer choice and access, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

April 2, 2019

Mr. Meadows introduced the following bill; which was referred to the Committee on the Judiciary

A BILL

To allow State-based, market-oriented, prescription drug negotiations to lower pharmaceutical drug prices, to encourage competition, to increase consumer choice and access, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "State-Based, Market-
- 5 Oriented, Prescription Drug Negotiations Act of 2019".

1	SEC. 2. ANTITRUST EXEMPTION FOR PRIVATE HEALTH IN-
2	SURER ISSUERS TO NEGOTIATE WHOLESALE
3	ACQUISITION PRICES OF PRESCRIPTION
4	DRUGS PURCHASED FROM DRUG MANUFAC-
5	TURERS.
6	It shall not be a violation of the antitrust laws for
7	one or more private health insurer issuers or their des-
8	ignated agents to jointly negotiate wholesale acquisition
9	prices of a prescription drug with a manufacturer of a pre-
10	scription drug with regards to the reimbursement policies
11	of the insurers of the manufacturer's drugs so long as no
12	one single wholesale acquisition price is jointly determined
13	between the insurance issuers or their designated agents.
14	SEC. 3. DEFINITIONS.
15	For purposes of this Act:
16	(1) Antitrust laws.—The term "antitrust
17	laws" has the meaning given it in subsection (a) of
18	the 1st section of the Clayton Act (15 U.S.C. 12(a)),
19	except that such term includes section 5 of the Fed-
20	eral Trade Commission Act (15 U.S.C. 45) to the
21	extent such section 5 applies to unfair methods of
22	competition.
23	(2) Health insurance issuer.—The term
24	"health insurance issuer" means an insurance com-
25	pany, insurance service, or insurance organization

- 1 fined in paragraph (3)) which is licensed to engage 2 in the business of insurance in a State and which is subject to State law which regulates insurance (with-3 4 in the meaning of section 514(b)(2) of the Employee 5 Retirement Income Security Act of 1974 (29 U.S.C. 6 1144(b)(2))). Such term does not include a group 7 health plan. 8 (3) Health maintenance organization.— 9 The "health organization" term maintenance 10 means— 11 (A) a federally qualified health mainte-12 organization (as defined in section 13 300e(a) of title 42 of the Code of Federal Reg-14 ulations), 15 (B) an organization recognized under State 16 law as a health maintenance organization, or 17 (C) a similar organization regulated under 18 State law for solvency in the same manner and 19 to the same extent as such a health mainte-
 - (4) Manufacturer.—The term "manufacturer" means anyone who is engaged in manufacturing, preparing, propagating, compounding, processing, packaging, repackaging, or labeling of a pre-

nance organization.

20

21

22

23

24

1	(5) Prescription drug.—The term "prescrip-
2	tion drug" means any human drug required by Fed-
3	eral law or regulation to be dispensed only by a pre-
4	scription, including finished dosage forms and active
5	ingredients subject to section 503(b) of the Federal
6	Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)).

7 SEC. 4. EFFECTIVE DATE.

8 This Act shall take effect on the date of the enact-9 ment of this Act but shall not apply with respect to con-10 duct that occurs before such date.

 \bigcirc